Start-up
SEAL Therapeutics AG
About Therapeutics
SEAL Therapeutics is developing its proprietary SEAL technology as a potential gene therapy for laminin-α2 deficient congenital muscular dystrophy (LAMA2 MD), a severe and progressive neuromuscular disease affecting children from birth. SEAL Therapeutics aims to team-up with and support a qualified pharma partner with experience in advanced gene therapy technologies for clinical development to ultimately make this innovative treatment approach available to patients.
- Founding: 2022
- Focus : Service
- Industry : Biotechnology, Healthcare, Pharma
Here you will find SEAL Therapeutics AG
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
